



March 28, 2013

For Immediate Release

## **UMN Pharma Announces Change in Representative Director (CEO)**

The following change in the representative director (CEO) was resolved at the UMN Pharma board of directors meeting held on March 28, 2013.

As of this date, this change officially ratifies the informal appointment in "UMN Pharma Announces Selection of Additional Representative Director and Change in Representative Director" that was announced on February 13, 2013.

### **Details**

#### **1. Reason for Change**

The Flublok® influenza vaccine of Protein Sciences Corporation, which is provided to UMN Pharma under an exclusive license, was approved for use by the U.S. Food and Drug Administration (FDA) on January 16, 2013 (U.S. local time). Also, in Japan, the UMN-0502 for elderly people successfully passed the phase III clinical trial administered by Astellas Pharma on March 11, 2013. As a result, work for applying for approval of the UMN-0502, UMN-0501, and UMN-0901, which are currently under development, takes on even greater importance.

The central management issue in applying for approval is to ensure the starting of operations at the Gifu plant by UNIGEN Inc., a subsidiary of UMN Pharma, so that quality and other data required for the approval application can be obtained. The Gifu plant, located in Ikeda, Ibi district, Gifu prefecture, is currently under construction and will be a commercial biopharmaceutical manufacturing plant. The Gifu plant will provide a production system compliant with the GMP Ministerial Ordinance, and from a managerial standpoint, will require an enhanced financial management system for unit cost calculations and loans.

At UMN Pharma, our activities will be focused on R&D for new development projects such as UMN-2003, expansion into Asia for the UMN-0502, UMN-0501, and UMN-0901, receiving orders for biopharmaceutical product subcontracting manufacturing, and introducing new initiatives for providing new and improved corporate value.

In view of this management environment, the board of directors previously added the selection of Dr. Masahiro Michishita as representative director for the purpose of further enhancing future R&D functions for improving the management capability of the UMN Pharma Group. However, with the appointment of Tatsuyoshi Hirano as CEO of UNIGEN for the purpose of centralizing and enhancing the production functions and management functions in UNIGEN, the board of directors decided to appoint Dr. Masahiro Michishita as the CEO.

## 2. Change in Representative Director

Name	New Appointment	Previous Appointment
Masahiro Michishita	Chairman and CEO	Chairman
Tatsuyoshi Hirano	Director of UMN Pharma CEO of UNIGEN (Held concurrently)	CEO Director of UNIGEN (Held concurrently)

Note: UNIGEN Inc. is a consolidated subsidiary of UMN Pharma Inc.

## 3. Profile of New CEO

Name (Birth date)	Experience	No. of shares held
Masahiro Michishita (January 28, 1961)	June 1985	-
	April 1987	
	July 1991	
	April 1993	
	April 1994	
	September 1995	
	April 1997	
	April 1999	
	April 2004	
	February 2005	
	January 2011	
February 2013		
February 2013		

## 4. Date of Assuming Office

March 28, 2013

For Media Inquiries
General Affairs Division, UMN Pharma Inc. TEL: +81-45-263-9200 E-mail: <a href="mailto:press@umnpharma.com">press@umnpharma.com</a>